Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Cancer. 2010 Feb 15;116(4):863-70. doi: 10.1002/cncr.24834.
Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes.
The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNS-PTLD without evidence of systemic PTLD were investigated retrospectively.
The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival.
The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.
原发性中枢神经系统(CNS)移植后淋巴组织增生性疾病(PCNS-PTLD)是实体器官移植的罕见并发症。本研究的目的是定义该疾病的临床、影像学和病理学特征,并探讨治疗对患者预后的影响。
作者回顾了国际原发性 CNS 淋巴瘤协作组参与机构的数据库,对 34 例经病理证实且无全身 PTLD 证据的 PCNS-PTLD 患者进行了回顾性研究。
从移植到诊断 PCNS-PTLD 的中位时间为 4.4 年。疾病通常为多发病灶,累及脑的任何部位,但最常见于大脑半球,通常位于皮质下白质或基底节。影像学上,所有病变均呈均匀或环状增强。大多数患者需要脑活检才能确诊。大多数患者为单形性、EB 病毒(EBV)阳性的 B 细胞起源疾病。无论治疗类型如何,反应率均较高,中位生存期为 47 个月。年龄是唯一预测生存的因素。
本研究表明,PCNS-PTLD 通常是一种 EBV 诱导的 B 细胞淋巴瘤,对化疗或放疗治疗有反应,许多患者的生存预后良好。强烈建议采用积极的方法进行组织确诊和治疗。